Current concepts review: Evidence-based review of the role of aprotinin in blood conservation during orthopaedic surgery

Journal of Bone and Joint Surgery

Volumn 87, Issue 5, 2005, Pages 1129-1136

  Kokoszka, Agnieszka ^a,b   Kuflik, Paul ^a   Bitan, Fabien ^a   Casden, Andrew ^a   Neuwirth, Michael ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ST VINCENT S HOSPITAL MANHATTAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; PLACEBO; SERINE PROTEINASE INHIBITOR;

BLEEDING; BLOOD STORAGE; BOLUS INJECTION; BRONCHOSPASM; DEEP VEIN THROMBOSIS; ELECTIVE SURGERY; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEART SURGERY; HUMAN; LUNG EMBOLISM; OPERATION DURATION; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SPINE SURGERY; TOTAL HIP PROSTHESIS; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HIP; HIP ARTHROPLASTY; RANDOMIZED CONTROLLED TRIAL; SPINE; STATISTICS;

APROTININ; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD TRANSFUSION; HIP; HUMANS; ORTHOPEDIC PROCEDURES; RANDOMIZED CONTROLLED TRIALS; SERINE PROTEINASE INHIBITORS; SPINE;

EID: 20644440382     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.D.02240     Document Type: Review

References (45)

1. Kovesi T, Royston D. Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang. 2003;84:2-10.
2. Wells PS. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. Am J Ther. 2002;9:377-88.
3. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001;1:CD001886.
4. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-Operative Transfusion (ISPOT) Investigators. Anesth Analg. 1997;85:1258-67.
5. Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs. 2002;62:2193-211.
6. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs. 1999;57:233-60.
7. Donahue MA, Price PM. Aprotinin: antifibrinolytic and anti-inflammatory mechanisms of action in cardiac surgery with cardiopulmonary bypass. Dynamics. 2002;13:16-23.
8. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg. 2001;72:2169-75.
9. Bradfield JF, Bode AP. Aprotinin restores the adhesive capacity of dysfunctional platelets. Thromb Res. 2003;109:181-8.
10. Landis RC, Haskard DO, Taylor KM. New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 2001;72:S1808-13.
11. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma. 2003;54:908-14.
12. Vamvakas EC. Possible mechanisms of allogeneic blood transfusion- associated postoperative infection. Transfus Med Rev. 2002;16:144-60.
13. Higgins C. The risks associated with blood and blood product transfusion. Br J Nurs. 2000;9:2281-90.
14. Bernstein J. Evidence-based medicine. J Am Acad Orthop Surg. 2004;12:80-8.
15. Narayanan UG, Wright JG. Evidence-based medicine: a prescription to change the culture of pediatric orthopaedics. J Pediatr Orthop. 2002;22:277-8.
16. Sackett DL. Evidence-based medicine. Spine. 1998;23:1085-6.
17. Oxman AD, Sackett DL, Guyatt GH. Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. JAMA. 1993;270:2093-5.
18. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1993;270:2598-601.
19. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA. 1994;271:59-63.
20. Hayes A, Murphy DB, McCarroll M. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth. 1996;8:357-60.
21. Amar D, Grant FM, Zhang H, Boland PJ, Leung DH, Healey JA. Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery. Anesthesiology. 2003;98:337-42.
22. Cole JW, Murray DJ, Snider RJ, Bassett GS, Bridwell KH, Lenke LG. Aprotinin reduces blood loss during spinal surgery in children. Spine. 2003;28:2482-5.
23. Khoshhal K, Mukhtar I, Clark P, Jarvis J, Letts M, Splinter W. Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. J Pediatr Orthop. 2003;23:661-4.
24. Jeserschek R, Clar H, Aigner C, Rehak P, Primus B, Windhager R. Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study. J Bone Joint Surg Br. 2003;85:174-7.
25. Samama CM, Langeren O, Rosencher N, Capdevila X, Rouche P, Pegoix M, Berniere J, Coriat P. Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesth Analg. 2002;95:287-93, table of contents.
26. Langdown AJ, Field J, Grote J, Himayat H. Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty. J Arthroplasty. 2000;15:1009-12.
27. Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am. 2000;82:675-84.
28. Engel JM, Hohaus T, Ruwoldt R, Menges T, Jurgensen I, Hempelmann G. Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin. Anesth Analg. 2001;92:775-80.
29. Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine. 2001;26:1152-6.
30. Lentschener C, Cottin P, Bouaziz H, Mercier FJ, Wolf M, Aljabi Y, Boyer-Neumann C, Benhamou D. Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg. 1999;89:590-7.
31. Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovich J, d'Athis F. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology. 1998;88:50-7.
32. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg. 1995;80:343-8.
33. Thorpe CM, Murphy WG, Logan M. Use of aprotinin in knee replacement surgery. Br J Anaesth. 1994;73:408-10.
34. Janssens M, Joris J, David JL, Lemaire R, Lamy M. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology. 1994;80:23-9.
35. Singbartl G, Kantak S, Munkel H. Transfusion-related cost of adjunct aprotinin application in one-step infected hip revision arthroplasty - cost-minimizing analysis. Infusionsther Transfusionsmed. 2001;28:74-9.
36. Singbartl G, Kantak S, MunkeL H. Adjunct aprotinin administration is at least a cost-neutral blood saving measure in ineffective knee revision surgery. Curr Opin Clin Exp Res. 2001;3:146-54.
37. Kasper SM, Elsner F, Hilgers D, Grond S, Rutt J. A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiol. 1998;15:669-75.
38. Haas S. Aprotinin - a blood-saving substance. Infusionsther Transfusionsmed. 2002;29:151-5.
39. Haas S, Ketterl R, Stemberger A, Wendt P, Fritsche HM, Kienzle H, Lechner F, Blumel G. The effect of aprotinin on platelet function, blood coagulation and blood lactate level in total hip replacement - a double blind clinical trial. Adv Exp Med Biol. 1984;167:287-97.
40. Putnam JB Jr, Royston D, Zacharski LR, Vaporciyan AA. Serine protease inhibition: potential uses beyond control of blood loss. Contemp Surg Suppl. 2003; December:S1-11.
41. Royston D, Cardigan R, Gippner-Steppert C, Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? Anesth Analg. 2001;92:830-6.
42. Beckmann J, Mehlich A, Schroder W, Wenzel HR, Tschesche H. Preparation of chemically 'mutated' aprotinin homologues by semisynthesis. P1 substitutions change inhibitory specificity. Eur J Biochem. 1988;176:675-82.
43. Palmer JD, Francis JL, Pickard JD, Iannotti F. The efficacy and safety of aprotinin for hemostasis during intracranial surgery. J Neurosurg. 2003;98:1208-16.
44. Lentschener C, Benhamou D, Mercier FJ, Boyer-Neumann C, Naveau S, Smadja C, Wolf M, Franco D. Aprotinin reduces blood loss in patients undergoing elective liver resection. Anesth Analg. 1997;84:875-81.
45. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465-73.